Pemetrexed disodium is a guanine-derived antineoplastic agent that functions as a nucleic acid synthesis inhibitor through its binding to, and inhibition of, thymidylate synthase.
Pemetrexed disodium heptahydrate/培美曲赛二钠七水合物 细胞实验
Cell Line
Concentration
Treated Time
Description
References
CL141 lung cancer cells
100 nM
24 hours
To determine the effect of pemetrexed on PD-L1 expression and T cell activation
J Immunother Cancer. 2020 Nov;8(2):e001392.
A549 cells
250 nM
48 hours
Enhanced PD-L1 and HLA-G expression and glycosylation, and increased CTL cytotoxicity against A549 cells
Cancer Sci. 2023 Jul;114(7):2761-2773.
H1975 cells
50 nM
48 hours
Enhanced PD-L1 and HLA-G expression and glycosylation, and increased CTL cytotoxicity against H1975 cells
Cancer Sci. 2023 Jul;114(7):2761-2773.
Pemetrexed disodium heptahydrate/培美曲赛二钠七水合物 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Syngeneic mouse models
Intraperitoneal injection
50 mg/kg
Every 4 days for two cycles
To evaluate the combination effect of pemetrexed and anti-PD-L1 antibody on tumor growth inhibition
J Immunother Cancer. 2020 Nov;8(2):e001392.
NOD.Cg-PrkdcSCID/ll2rgtm1vst/Vst (NPG) mice
A549-Luc xenograft model
Tail vein injection
50 mg/kg
Once weekly for 2 weeks
Pemetrexed combined with dual immune checkpoint blockade (anti-PD-L1 and anti-HLA-G) significantly promoted CTL-mediated cytotoxicity and inhibited tumor growth
搜索
